Search

Eric Ailor Phones & Addresses

  • 6801 Thornwood St, San Diego, CA 92111 (858) 694-0161
  • 3239 Fox Run Row, San Diego, CA 92111 (858) 694-0161
  • 1111 Park Ave, Baltimore, MD 21201 (410) 669-3173 (410) 669-7314
  • Heathrow, FL
  • Cockeysville, MD

Work

Company: Mapp biopharmaceutical inc Oct 2015 Position: Director

Education

Degree: Doctorates, Doctor of Philosophy School / High School: The Johns Hopkins University Specialities: Chemical Engineering

Skills

Cell Culture • Drug Discovery • Molecular Biology • Biotechnology • Pharmaceutical Industry • Cell • Life Sciences • Protein Chemistry • Biopharmaceuticals • Protein Expression

Industries

Biotechnology

Resumes

Resumes

Eric Ailor Photo 1

Director

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Mapp Biopharmaceutical Inc
Director

Bionomics Inc 2013 - Aug 2015
Senior Scientist

Sorrento Therapeutics, Inc. 2011 - 2013
Senior Scientist

Biogen 2006 - 2011
Scientist Ii

Biogen 2001 - 2006
Scientist I
Education:
The Johns Hopkins University
Doctorates, Doctor of Philosophy, Chemical Engineering
Howard University
Bachelors, Bachelor of Science, Chemical Engineering
Skills:
Cell Culture
Drug Discovery
Molecular Biology
Biotechnology
Pharmaceutical Industry
Cell
Life Sciences
Protein Chemistry
Biopharmaceuticals
Protein Expression

Publications

Us Patents

Inhibition Of Apoptosis Process And Improvement Of Cell Performance

View page
US Patent:
20030064510, Apr 3, 2003
Filed:
Jul 10, 2002
Appl. No.:
10/191052
Inventors:
Mitchell Reff - San Diego CA, US
Eric Ailor - San Diego CA, US
Michael Betenbaugh - Baltimore MD, US
Bruno Figueroa - Baltimore MD, US
Marie Hardwick - Baltimore MD, US
Assignee:
IDEC Pharmaceuticals Corporation - San Diego CA
International Classification:
A61K038/19
A61K039/395
A61K038/43
C12P021/02
C12N005/06
US Classification:
435/325000, 424/144100, 424/085100, 514/012000, 424/094100, 435/069100
Abstract:
The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.

Method To Increase Protein Production In Culture

View page
US Patent:
20050106222, May 19, 2005
Filed:
Jun 10, 2004
Appl. No.:
10/864348
Inventors:
Eric Ailor - San Diego CA, US
Mitchell Reff - San Diego CA, US
International Classification:
A61K009/70
B32B027/12
US Classification:
424443000, 442123000
Abstract:
A new recombinant protein production methodology has been discovered for expression of genes of interest. This should be useful for low or poorly expressing genes and in cellular production of high levels of proteins when such high levels may be detrimental or stressful to cells. Isolated polynucleotides encoding a spliced form XBP-1, ATF6, and eIF2α S51A are disclosed. Expression vectors comprising these polynucleotides are useful in increasing the specific cellular productivity in a cell expressing a polypeptide of interest by augmenting the unfolded protein response in a cell. Finally, methods to increase specific cellular productivity in mammalian cells using the above mentioned polynucleotides are also disclosed.

Antibodies That Bind Lgr4

View page
US Patent:
20160046723, Feb 18, 2016
Filed:
Jun 17, 2015
Appl. No.:
14/741696
Inventors:
- San Diego CA, US
Kristen M. Smith - San Clemente CA, US
Peter Chu - San Diego CA, US
Lioudmila A. Campbell - San Diego CA, US
Eric Ailor - San Diego CA, US
International Classification:
C07K 16/30
Abstract:
Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
Eric N Ailor from San Diego, CA, age ~63 Get Report